Матричная РНК белков системы «интерлейкин-2 — рецептор интерлейкина-2» в опухолевых очагах
Диссертация
В образцах опухолевых очагов было проведено сопоставление частоты обнаружения мРНК IL-2Ra с особенностями транскриптома раковых клеток. В частности, осуществлено сравнение частоты детекции мРНК IL-2Ra с частотой обнаружения мРНК 22 раково-тестикулярных белков, а также 11 альтернативных вариантов мРНК трех дифференцировочных белков. Установлено, что при РТК мРНК CD25Exo4Del встречается чаще… Читать ещё >
Список литературы
- Князев Д.И., Новиков Д. В., Сахарнова Т. А. и др. Экспрессия гена ICAM-1 в опухолевых клетках больных раком толстого кишечника // Вестник Нижегородского университета им. Н. И. Лобачевского. 2010. — Т. 2, № 2. -С. 528−531.
- Новиков В.В., Караулов А. В., Барышников А. Ю. Растворимые формы мембранных антигенов клеток иммунной системы. М.: Медицинское информационное агентство. 2008. — 249 с.
- Новиков В.В. Молекулярная биология опухолевого роста // Онкология. Руководство для врачей в 2-х томах. Под ред. Б. Е. Шахова и др. Н. Новгород: НГМА. 2010. — Т. 1.С. 69−84.
- Новиков В.В. Особенности транскриптома опухолевых клеток // Рос. биотерап. журнал. Тез. IX Всерос. научно-практ. конференции с межд. участием «Отечественные противоопухолевые препараты». 2010. — № 2. -С. 55.
- Рыжов С.В., Новиков В. В. Молекулярные механизмы апоптотических процессов // Рос. биотерап. журн. 2002. — Т. 1, № 3. — С. 27−33.
- Симбирцев А. С. Интерлейкин-2 и рецепторный комплекс интерлейкина-2 в регуляции иммунитета // Иммунология. 1998. — № 6. — С. 3−8.
- Ярилин А.А., Добротина Н. А. Введение в современную иммунологию. -Н.Новгород: ННГУ, 1997. 238 с.
- Antony Р.А., Paulos С.М., Ahmadzadeh М. et al. Interleukin-2-dependent mechanism of tolerance and immunity in vivo // J. Immunol. 2006. — V. 176, № 9. — P. 5255−66.
- Asao H., Okuyama C., Kumaki S. et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex // J. Immunol. 2001. -V. 167, № l.-p. 1−5.
- Aydin F., Yilmaz M., Ozdemir F. et al. Correlation of serum IL-2, IL-6, and IL-10 levels with IPI in patients with aggressive non-Hodgkin's lymphoma // Am. J. Clin. Oncol. 2002. — V. 25, № 6. — P. 570−72.
- Bach J. F. Regulatory T cells under scrutiny // Nat. Rev. Immunol. 2003. — V. 3, № 3. — P. 189.
- Baecher-Allan C., Brown J. A., Freeman G. J., Hafler D. A. CD4+CD25hlgh regulatory cells in human peripheral blood // J. Immunol. 2001. — V. 167, № 3. -P. 1245−1253.
- Baik Y.H., An J.Y., Noh J.H. et al. Can serum interleukin-2 receptoralpha predict lymph node metastasis in early gastric cancer? // J. Korean Surg. Soc. — 2012. — V. 82, № 3.-P. 143−148.
- Barnhart B.C., Lee J.C., Alappat E.C., Peter M.E. The death effector domain protein family // Oncogene. 2003. — V. 22, № 53. — P. 8634−8644.
- Bazan J.F. Unraveling the structure of IL-2 // Science. 1992. — V. 257, № 5068. -P. 410−413.
- Bien E., Balcerska A., Kuchta G. Serum level of soluble interleukin-2 receptor alpha correlates with the clinical course and activity of Wilms' tumour and soft tissue sarcomas in children // Biomarkers. 2007. — V. 12, № 2. — P. 203−213.
- Bien E., Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review // Biomarkers. 2008. -V. 13, № 1. — P. 1−26.
- Bien E., Balcerska A. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin’s lymphoma // Scand. J. Immunol. 2009. — V. 70, № 5. — P. 490−500.
- Birney E., Andrews T.D., Bevan P. et al. An overview of Ensembl // Genome Res. 2004. — V. 14, № 5. — P. 925−928.
- Brentani H., Caballero O.L., Camargo A.A. et al. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags // Proc. Natl. Acad. Sci. USA. 2003. — V. 100, № 23. — P. 1 341 813 423.
- Brinkmann U., Vasmatzis G., Lee B. et al. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database // Cancer Res. 1999. — V. 59, № 7. — P. 1445−1448.
- Burton J., Goldman C.K., Rao P. et al. Association of intercellular adhesion molecule 1 with the multichain high-affinity interleukin 2 receptor // Proc. Natl. Acad. Sci. USA. 1990. — V. 87, № 18. — P. 7329−7333.
- Cabrera R., Ararat M., Eksioglu E.A. et al. Influence of serum and solubleCD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma // Scand. J. Immunol. 2010. — V. 72, № 4. P. 293−301.
- Cantrell D.A., Smith K.A. The interleukin-2 T-cell system: a new cell growth model // Science. 1984. -V. 224, № 4655. — P. 1312−1316.
- Carlile G.W., Smith D.H., Wiedmann M. A non-apoptotic role for Fas/FasL in erythropoiesis // FEBS Letters. 2009. — V. 583, № 4. — P. 848−854.
- Castrignano T., D’Antonio M., Anselmo A. et al. ASPicDB: a databaseresource for alternative splicing analysis // Bioinformatics. 2008. — V. 24, № 10. — P. 1300−1304.
- Champagne B., Tremblay P., Cantin A., Pierre Y.S. Proteolytic cleavage of ICAM-1 by human neutrophil elastase 1 // J. Immunology. 1998. — V. 161, № 11.-P. 6398−6405.
- Chaput N., Louafi S., Bardier A. et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue // Gut. 2009. -V. 58, № 4. — P. 520−529.
- Chiou S.H., Sheu B.C., Chang W.C. et al. Current concepts of tumor-infiltrating lymphocytes in human malignancies // Reprod. Immunol. 2005. — V. 67. — P. 35−50.
- Cho B., Lim Y., Lee D.Y. et al. Identification and characterization of a novel cancer/testis antigen gene CAGE // Biochem. Biophys. Res. Commun. 2002. -V. 292, № 3. p. 715−726.
- Choi C. Homo sapiens interleukin-2 receptor mRNA, alternatively spliced, partial cds // Submitted Neurology, Yonsei University, Shinchon-dong, South Korea 1997. — URL: http://www.ncbi.nlm.nih.goV/nuccore/AF008556.l.
- Chomez P., Backer O., Bertrand M. et al. An Overview of the MAGE Gene Family with the Identification of All Human Members of the Family 1 // Cancer Reseach. -2001. V. 61. — P. 5544−5551.
- Cosman D. Cloning, sequence and expression of human interleukin-2 receptor // Nature. 1984. — V. 312, № 5996. — P. 768−771.
- Deaglio S., Mehta K., Malavasi F. Human CD38: a ®evolutionary story of enzymes and receptors // Leukemia Res. 2001. — V. 25, № 1. — P. 1−12.
- Dummer R., Posseckert G., Sugamura K. et al. Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta, and gamma chains // J. Interferon Cytokine Res. 1996. — V. 16.-P. 315−320.
- Eckmann L., Jung H.C., Schurer-Maly C. et al. Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin 8 // Gastroenterology. 1993. — V. 105, № 6. — P. 1689−1697.
- El Houda Agueznay N., Badoual C., Hans S. et al: Soluble inteleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationship // Clin. Exp. Immunol. -2007. V. 150, № 1. — P. 114−123.
- Ferrari S., Cannizzaro L.A., Battini R. et al. The gene encoding human vimentin is located on the short arm of chromosome 10 // Am. J. Hum. Genet. 1987. — V. 41.-P. 616−626.
- Fisher J.R., Schindel M., Bulzebruck H. et al. Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer // Ann. Oncol. 1997. — V. 8. — P. 457−461.
- FitzGerald D.J., Wayne A.S., Kreitman R.J., Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates // Cancer Res. -2011. V. 71, № 20. — P. 6300−6309.
- Fontenot J.D., Gavin M. A., Rudensky A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells // Nat. Immunol. 2003. — V. 4, № 4.-P. 330−336.
- Frankish A., Mudge J.M., Thomas M., Harrow J. The importance of identifyingalternative splicing in vertebrategenomeannotation // Database (Oxford). 2012. — URL: http://database.oxfordjournals.org/content/2012/ bas014.
- Frey D.M., Droeser R.A., Viehl C.T. et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients // Int. J. Cancer. 2010. — V. 126, № 11. — P. 2635−2643.
- Fujita T., Takaoka C., Matsui H., Taniguchi T.: Structure of the human interleukin-2 gene // Proc. Natl. Acad. Sci. USA. 1983. V. 80. — P. 7437−7441.
- Garcia-Tunnon I., Ricote M., Ruiz A. et al. Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study // Breast Cancer Res. 2004. — V. 6, № l.-P. 1−7.
- Gesbert F., Delespine-Carmagnat M., Bertoglio J. Recent advances in the understanding of interleukin-2 signal transduction // J. Clin. Immunol. 1998. -V. 18, № 5.-P. 307−320.
- Gjerstorff M., Kock K., Nielsen O. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development // Human Reproduction. 2007. — V. 1. — P. 1−8.
- Glaser R., Andridge R., Yang E.V. et al. Tumor site immunemarkers associated with risk for subsequent basal cell carcinomas // PLoS One 2011. — V. 6, № 9. -URL: http://www.plosone.org/article/info%3Adoi%2 °F 10.1371%2Fjournal.pone. 25 160.
- Graveley B.R. Alternative splicing: increasing diversity in the proteomic world // Trends Genet. 2001. — V. 17, № 2. — P. 100−107.
- Grungreiff K., Reinhold D., Ansorge S. Serum concentrations of sIL-2R, IL-6, TGF-betal, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha // Cytokine. 1999. — V. 11, № 12. — P. 1076−1080.
- Gupta S., Zink D., Korn B. et al. Strengths and weaknesses of EST-based prediction of tissue-specific alternative splicing // BMC Genomics. 2004. — V. 5. -P. 72.
- Hamai A., Meslin F., Benhalam H. et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway // Cancer Res. 2008. — V. 68, № 23. — P. 9854−9864.
- Huang A, Quinn H., Glover C. et al. The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation // Cancer Immunol. Immunother. 2002. — V. 51, № 1. — P. 5357.
- Hunt M.J., Halliday G.M., Weedon D. et al. Regression in basal cell carcinoma: an immunohistochemical analysis // Brit. J. Dermatol. 1994. — V. 130, № 1. — P. 1−8.
- Ikeguchi M., Hirooka Y. Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas // Onkologie. 2005. — V. 28. — P. 255−259.i t
- Ishida N., Kanamori H., Noma T. et al. Molecular cloning and structure of the human interleukin 2 receptor gene // Nucleic Acids Research. 1985. — V.13, № 21.-P. 7579−7589.
- Jmal A., Ghanem A., Boussen H. et al. Seric soluble interleukin-2 receptor alpha in nasopharyngeal carcinoma in Tunisia. Prospective study about 45 cases // Tunis Med. 2007. — V. 85, № 8. — P. 651−654.
- Jo S.A., Hwang S.H., Chang C.L. et al. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Ra) in patients with non-Hodgkin's lymphoma // Korean J. Lab. Med. 2010. — V. 30, № 6. — P. 600−605.
- Johnston J.A., Kawamura M, Kirken R.A. et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2 // Nature. 1994. — V. 370, № 6485.-P. 151−153.
- Jonuleit H., Schmitt E. The regulatory T cell family: distinct subsets and their interrelations // J. Immunol. 2003. — V. 171, № 12. — P. 6323−6327.
- Kasprzak A., Olejniczak K., Przybyszewska W., Zabel M. Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours // Folia Morphol. 2007. — V. 66. — P. 159−166.
- Kawai Y., Kaidoh M., Ohhashi T. MDA-MB-231 produces ATP-mediated ICAM-1 -dependent facilitation of the attachment of carcinoma cells to human lymphatic endothelial cells // Am. J. Physiol. Cell Physiol. 2008. — V. 295, № 5. -P. 1123−1132.
- Kelleher D., Pandol S.J., Kagnoff M.F. Phorbol myristate acetate induces IL-2 secretion by HUT 78 cells by a mechanism independent of protein kinase C translocation // Immunology. 1988. — V. 65, № 3. — P. 351−355.
- Kikuchi E., Yamazaki K., Nakayama E., Sato S. Prolonged survival of patients with lung adenocarcinoma expressing XAGE-lb and HLA class I antigenl // Cancer Immunity. 2008. — V. 8. — P. 13−16.
- Kim H.P., Kim B.G., Letterio J., Leonard W.J. Smad-dependentcooperative regulation of interleukin 2 receptor alpha chain gene expression by T cell receptor and transforming growth factor-beta // J. Biol. Chem. 2005. — V. 280, № 40. -P. 34 042−34 047.
- Kondo M., Takeshita T., Ishii N. et al. Sharing of the interleukin 2 (IL-2) receptor y chain between receptors for IL-2 and IL-4 // Science. 1993. — V. 262, № 5141.-P. 1874−1877.
- Kono N., Kanda Y., Yamamoto R. et al. Prognostic signifi cance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan // Leukemia and Lymphoma. 2000. — V. 37. — P. 151−156.
- Kotlajich M.V., Hertel K.J. Death by Splicing: Tumor Suppressor RBM5 Freezes Splice-Site Pairing // Molecular Cell. 2008. — V. 32. — P. 162−164.
- Kreitman R.J., Arons E., Stetler-Stevenson M. Et al. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia // Leuk. Lymphoma. 2011. — V. 52. — P. 82−86.
- Kuhn D.J., Dou Q.P. The role of interleukin-2 receptor alpha in cancer // Front. Biosci. -2005. V. 10-P. 1462−1474.
- Lange B.J., Yang R.K., Gan J. et al. Soluble interleukin-2 receptora activation in a Children’s Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia // Pediatr. Blood Cancer. 2011. — V. 57, № 3. -P. 398−405.
- Leonard W.J., Depper J.M., Uchiyama T. et al. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor- partial characterization of the receptor // Nature. 1982. — V. 300, № 5889. — P. 267−269.
- Leonard W.J. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor // Nature. 1984. — V. 311, № 5987. — P. 626−631.
- Leonard W.J., Donlon T.A., Lebo R.V., Greene W.C. Localization of the gene encoding the human interleukin-2 receptor on chromosome 10 // Science. 1985.- V. 228, № 4707. P. 1547−1549.
- Lin C., Mak S., Meitner P. A. et al. Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma // Gene. 2002. — V. 285. — P. 269 278.
- Lin W.C., Yasumura S., Whiteside T. L. Transfer of interleukin 2 receptor genes into squamous cell carcinoma. Modification of tumor cell growth // Arch. Otolaryngol. Head Neck Surg. 1993. — V. 119. — P. 1229−1235.
- Lin W.C., Yasumura S., Suminami Y. et al. Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth // J. Immunol. 1995.-V. 155.-P. 4805−4816.
- Liparoto S.F., Ciardelli T.L. Biosensor analysis of the interleukin-2 receptor complex // J. Mol. Recognit. 1999. — V. 12, № 5. — P. 316−321.
- Loose D., Signore A., Bonanno E. et al. Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck // Cancer Biother. Radiopharm. 2008. — V. 23, № 1. — P. 25−33.
- Lowe C.E., Cooper J.D., Brusko T. et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes // Nature Genet. 2007. — V. 39. — P. 1074−1082.
- Lund F., Solvason N.J., Grimaldi C.R., Michael E. Parkhouse and Maureen Howard Murine CD38: an immunoregulatory Ectoenzyme // Immunology Today.- 1995. V. 16, № 10. — P. 469−473.
- Luo B., Carman C.V., Springer T.A. Structural basis of integrin regulation and signaling // Ann. Rev. Immunol. 2007. — V 25. — P. 619−647.
- Matutes E. Novel and emerging drugs for rarer chronic lymphoid leukaemias // Curr. Cancer Drug. Targets. 2012. — V. 12, № 5. — P. 484−504.
- McDoniels-Silvers A.L., Stoner G.D., Lubet R.A., You M. Differential expression of critical cellular genes in human lung adenocarcinomas andsquamous cell carcinomas in comparison to normal lung tissues // Neoplasia. -2002.-V. 4.-P. 141−150.
- Mellgren K., Hedegaard C.J., Schmiegelow K., Muller K. Plasma cytokine profiles at diagnosis in pediatric patients with non-Hodgkin lymphoma // J. Pediatr. Hematol. Oncol. 2012. — V. 34, № 4. — P. 271−275.
- Mercken L., Moras V., Hemon L. et al. An exon 5-deleted mRNA encodes a functional interleukin 2 receptor alpha-subunit // Biochem. Biophys. Res. Commun. 1991. — V. 180, № 3.-P. 1390−1395.
- Minami Y., Kono T., Miyazaki T., Taniguchi T. The IL-2 receptor complex: its structure, function and target genes // Annu Rev. Immunol. 1993. — V. 11.-P. 245−267.
- Mitsui F., Aikata H., Hashimoto Y. et al. A first case of hepatic angiosarcoma treated with recombinant interleukin-2 // Hiroshima J. Med. Sei. 2011. — V. 60, № 4.-P. 91−96.
- Miyawaki T., Uehara T., Nibu R. et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood // J. Immunol. 1992. — Vol. 149. — P. 3753−3758.
- Miyazaki T., Manuyama M., Yamada G. et al. The integrity of the conserved 'WS motif common to IL-2 and other cytokines receptors is essentials for ligand binding and signal transduction // EMBO J. 1991. — V. 10. — P. 3191−3197.
- Moon J.J., Rubio E.D., Martino A. et al. A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor // J. Biol. Chem. 2004. — V. 279, № 7. — P. 5520−5527.
- Nagata S., Golstein P. The Fas death factor // Science. 1995. — V. 267. — P. 1449−1456.
- Nelson B.H. IL-2 regulatory T cells, and tolerance // J. Immunol. -2004. V. 172.-P. 3983−3988.
- Niitsu N., Iijima K., Chizuka A. A high serum-soluble interleukin-2 recept or level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma // Eur. J. Haematol. 2001. — V. 66. — P. 24−30.
- Nikaido T., Shimizu A., Ishida N. et al. Molecular cloning of cDNA encoding human interleukin-2 receptor // Nature. 1984. — V. 311, № 5987. — P. 631−635.
- Noguchi M., Adelstein S., Cao X., Leonard W.J. Characterization of the human interleukin-2 receptor gamma chain gene // J. Biol. Chem. 1993. — V. 268, № 18.-P. 13 601−13 608.
- Novikov D. V., Belova T. V., Plekhanova E. S. et al. Early Detection of Cancer/Testis mRNAs in Tumor Cells Circulating in the Peripheral Blood of Colorectal Cancer Patients // Molecular Biology. 2012. — V. 46, № 5. — P. 687 692.
- Ohta M., Tanaka F., Sadanaga N. et al. Expression of the TRAG-3 gene in human esophageal cancer: The frequent synchronous expression of MAGE-3 gene // Oncology Reports. 2006. — V. 15. — P. 1529−1532.
- Old L.J. Cancer/testis (CT) antigens a new link between gametogenesis and cancer // Cancer Immun. — 2001. — V. 1. — P. 1−9.
- Otte M., Zafrakas M., Riethdorf L. et al. Pantel MAGE-A Gene Expression Pattern in Primary Breast Cancer // Cancer Research. 2001. — V. 61. — P. 66 826 687.
- Ozdemir F., Aydin F., Yilmaz M. et al. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive non-Hodgkin's lymphoma (NHL) // J. Exp. Clin. Cancer Res. 2004. — V. 23. — P. 485−488.
- Papoff G., Hausler P., Eramo A. et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor // J. Biol. Chem. 1999. — V. 274. — P. 3241−3250.
- Park J., Kwon T.K., Kim I. et al. A new strategy for the diagnosis of MAGE-expressing cancers // J. Immunol. 2002. — V. 266. — P. 79−86.
- Peuchmaur M., Emilie D., Crevon C. et al. IL-2 mRNA expression in Tacpositive malignant lymphomas // Am. J. Pathol. 1990. — V. 136. — P. 383 390.
- Piancatelli D., Romano P., Sebastiani P. et al. Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression // J. Immunother. 1999. — V. 22, № 1. — P. 25−32.
- Plaen E., Smit C., Boucouey M. et al. Genes expressed in cancer and germ line cells // Immunogenetics. 2005. — V. 13. — P. 195−198.
- Qiu F.B., Wu L.Q., Lu Y. et al. Predominant expression of Thl-type cytokines in primary hepatic cancer and adjacent liver tissues // Hepatobiliary Pancreat. Dis. Int.-2007.-V. 6.-P. 63−66.
- Reichert T.E., Kashii Y., Stanson J. et al. The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines // Br. J. Cancer. 1999. — V. 81, № 5.-P. 822−831.
- Reinecker H.C., Podolsky D.K. Human intestinal epithelial cells express functional cytokine receptors sharing the common gamma c chain of the interleukin 2 receptor // Proc. Natl. Acad. Sci. USA. 1995. — V. 92, № 18. — P. 8353−8357.
- Rickert M., Boulanger M.J., Goriatcheva N., Garcia K.C. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma© receptors // J. Mol. Biol. 2004. -V. 339, № 5. P. 1115−1128.
- Rickert M., Wang X.Q., Boulanger M.J. et al. The structure of interleukin-2 complexed with its alpha receptor // Science. 2005. — V. 308, № 5727-P. 1477−1480.
- Rimoldi D., Salvi S., Hartmann F. et al. Expression of IL-2 receptors in human melanoma cells // Anticancer Res. 1993. — V. 13. — P. 555−564.
- Robb R.J., Munck A., Smith K.A. T cell growth factor receptors. Quantitation, specificity, and biological relevance // J. Exp. Med. 1981. — V. 154, № 5. — P. 1455−1474.
- Robb R.J., Kutny R.M. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein // J. Immunol. 1987. — V. 139, № 3. — P. 855−862.
- Rosenberg S.A. Raising the bar: the curative potential of human cancer immunotherapy // Sci. Transl. Med. 2012. — V. 4, № 127. — P. 127.
- Rossetti G., Collinge M., R. Bender J. et al. Integrin-dependent regulation of gene expression in leukocytes // Immunological Reviews. 2002. — V. 186. — P. 189−207.
- Rothenberg E.V., Diamond R.A. Costimulation by interleukin-1 of multiple activation responses in a developmentally restricted subset of immature thymocytes // Eur. J. Immunol. 1994. — V. 24, № 1. — P. 24−33.
- Royuela M., De Miguel M. P., Bethencourt F. R. et al. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis // Growth Factors. 2000. — V. 18. -P. 135−146.
- Rubin L.A., Kurman C.C., Fritz M.E. et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro // J. Immunol. 1985. — V. 135, № 5.-P. 3172−3177.
- Rubin L.A., Nelson D.L. The soluble interleukin-2 receptor: biology, function, and clinical application // Ann. Intern. Med. 1990. — V. 113, № 8. — P. 619−627.
- Russell S.M., Keegan A.D., Harada N. et al Interleukin-2 receptor gammachain: a functional component of the interleukin-4 receptor // Science. -1993.-V. 262.-P. 1880−1883.
- Sakata H., Murakami S., Hirayama R. Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer // Int. J. Clin. Oncol. 2002. — V. 7, № 5. p. 312−317.
- Salama P., Phillips M., Grieu F. et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer // J. Clin. Oncol. 2009. — V. 27, № 2. — P. 196−192.
- Sarquis M.S., Agrawal S., Shen L. et al. Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome // Am. J. Hum. Genet. 2006. — V. 79, № 1. — P. 23−30.
- Secor E.R., Singh J.A., Guernsey L.A. et al. Bromelain treatment reduces CD25 expression on activated CD4(+) T cells in vitro // Int. Immunopharmacol. -2009. V.9, № 3. — P. 340−346.
- Sharfe N., Dadi H.K., Shahar M., Roifman C.M. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor // Proc. Natl. Acad. Sei. USA. 1997. — V. 94, № 7. — P. 3168−3171.
- Sharon M., Klausner R.D., Cullen B.R. et al. Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions // Science. 1986. — V. 234, № 4778. — P. 859−863.
- Shibuya H., Yoneyama M., Nakamura Y. et al. The human interleukin-2 receptor beta-chain gene: Genomic organization, promotor analysis and chromosomal assignment // Nucleic Acids Res. 1990. — V. 18. — P. 3697−3703.
- Simpson A.J.G., Caballero O.L., Jungbluth A. et al. Cancer/Testis antigens, gametogenesis and cancer // Nature Reviews. 2005. — V. 5. — P. 615−625.
- Smith K. A. The quantal theory of immunity // Cell Res. 2006. — V. 16, № 1. -P. 11−19.
- Spachacz R., Kasprzak A., Stefanska K. et al Tissue expression of cytokines (IL-la, IL-2, IL-6, IL-12, TNF-a) in B-cell lymphomas in children // Folia Morphol. 2003. — V. 62. — P. 483−85.
- Stamm S., Ben-Ari S., Rafalska I. et al. Function of alternative splicing // Gene. 2005. — V. 344. — P. 1−20.
- Stasi R., Zinzani L., Galieni P. et al. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma // Br. J. Haematol. 1994. — V. 88, № 4. — P. 770−777.
- Stauber D.J., Debler E.W., Horton P.A. et al. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor // Proc. Natl. Acad. Sci. USA. 2006. — V. 103, № 8. — P. 2788−2793.
- Stein U., Walther W., Shoemaker R.H. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells // J. Natl. Cancer Inst. 1996. — V. 88, № 19. — P. 1383−1392.
- Stevens A.C., Matthews J., Andres P. et al. Interleukin-15 signals T84 colonic epithelial cells in the absence of the interleukin-2 receptor beta-chain // Am. J. Physiol. 1997. — V. 272. — P. 1201−1208.
- Tanaka T., Saiki O., Doi S. et al. Expression of novel interleukin 2 binding molecules and their functional roles in human B cell differentiation // J. Clin. Invest. 1988. -V. 82, № 1. — P. 316−321.
- Taniguchi T., Matsui H., Fujita T. et al. Structure and expression of a cloned cDNA for human interleukin-2 // Nature. 1983. — V. 302. — P. 305−310.
- Taniguchi T., Minami Y. The IL-2iIL-2 receptor system: a current overview // Cell.- 1993.-V. 73.-P. 5.
- Tian H., Cao B., Wang S. Clinical significance of detection of IL-2R for non-small cell lung cancer // Zhongguo Fei Ai Za Zhi. 1998. — V. 1, № 2. — P. 90−91.
- Tilli T.M., Franco V.F., Robbs B.K. et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression // Mol. Cancer Res. 2011. — V. 9, № 3. -P. 280−293.
- Trauth B.C., Klas C., Peters A.M. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis // Science. 1989. — V. 245, № 4915. — P. 301−305.
- Tsudo M., Kitamura F., Miyasaka M. Characterization of the interleukin-2 receptor beta chain using three distinct monoclonal antibodies // Proc. Natl. Acad. Sci. USA. 1989. — V. 86. — P. 1982−1986.
- Vamosi G., Bodnar A., Vereb G. et al. IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells // Proc. Natl. Acad. Sci. USA. -2004. V. 101.-P. 11 082−11 087.
- Van der Bruggen P., Traversari C., Chomez P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma // Science. -1991.-V. 254.-P. 1643−1647.
- Waldmann T.A. The interleukin-2 receptor // J. Biol. Chem. 1991. — V. 266. -P. 2681−2685.
- Waldmann T.A., O’Shea J. The use of antibodies against the IL-2 receptor in transplantation // Curr. Opin. Immunol. 1998. — V. 10, № 5. — P. 507−512.
- Waldmann T.A. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma // Oncogene. 2007. — V. 26, № 25. — P. 3699−3703.
- Wan L., Cai H., Yang H. et al. Biotechnological Products and Process Engineering // Applied Microbiol, and Biotech. 2008. — V. 81, № 1. — P. 33−41.
- Wang G.S., Cooper T.A. Splicing in disease: Disruption of the splicing code and the decoding machinery // Nat. Rev. Genet. 2007. — V. 8, № 10. — P. 749 761.
- Wang Q., Li B., Liu B. et al. Polymorphisms of the ICAM-1 exon 6 (E469K) are associated with differentiation of colorectal cancer // J. Exp. Clin. Cancer Res. 2009.-V. 28. -P. 139−145.
- Wang X., Rickert M., Garcia K.C. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors // Science. 2005. — V. 310, № 5751.-P. 1159−1163.
- Xu Q., Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences // Nucleic Acids Res. 2003. — V. 31, № 19. — P. 5635−5643.
- Yano T., Fukuyama Y., Yokoyama H. et al. Interleukin-2 receptors in pulmonary adenocarcinoma tissue // Lung Cancer. 1996. — V. 16, № 1. — P. 1319.
- Yoshimatsu K., Kuhara K., Itagaki H. et al. Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer // Anticancer Res. 2008. — V. 28, № IB. — P. 373−378.
- Zendman A., Van Kraats A., Weidle U. et al. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing’s sarcoma // Int. J. Cancer. 2002. — V. 99. — P. 361 369.
- Zendman A., Ruiter D., Van Muijen G. Cancer/testis-associated genes: identification, expression profile, and putative function // Journal of cellular physiology. 2003. — V. 194. — P. 272−288.
- Zmuidzinas A., Mamon H.J., Roberts T.M., Smith K.A. Interleukin-2-triggered Raf-1 expression, phosphorylation, and associated kinase activity138V